Moreover, after the combination of azacytidine with the IDH2 inhibitor AG-221, it can alleviate abnormal changes in DNA methylation, causing a decrease in the number of leukemia cells, which in turn is consistent with anti-leukemia activity to enhance sensitivity [104–106]. The gene discussed is IDH2; the disease is leukemia.